Mice with cancer that were given small daily doses of ibuprofen had smaller
tumors and were less likely to die of colon cancer, they told a meeting.
"Now we want to do some more studies," said Dr. Michael Wolfe, a
gastroenterologist at the Boston University School of Medicine, who led the
study.
"What was really, to us, remarkable is the dose we used in these animals is
equivalent to 100 mg of ibuprofen in a human."
That is about half the amount contained in a standard tablet of ibuprofen.
Several studies have shown that people who take aspirin, ibuprofen and
related drugs called non-steroidal anti-inflammatory drugs, or NSAIDS, have a
lower risk of colon cancer.
The mechanism seems to be compounds called COX-1 and COX-2, both of which
NSAIDS interfere with.
But Wolfe said no one had tested NSAIDS as a potential cancer therapy.
Ibuprofen seemed to affect tumor cells in lab dishes, so he tried using
laboratory mice that had been infected with colon cancer cells. These mice
always develop tumors and die if not treated.
They treated the mice for 21 days with either ibuprofen alone, or with
ibuprofen added to the standard colon cancer drugs irinotecan, sold by Pfizer
under the brand name Camptosar, or 5-fluororacil.
By day 50, all the untreated mice had died. But 20 percent of the mice
treated with ibuprofen alone died, compared to 20 percent given Camptosar and
just 10 percent given ibuprofen plus Camptosar. But 70 percent of the mice that
got 5-fluororacil alone or with ibuprofen died.
Ibuprofen and 5-fluororacil seem to interfere with one another, Wolfe said.
The findings were presented on Wednesday to a meeting in New Orleans of cancer
and digestive experts called Digestive Disease Week.
"I'd love to see a study done for the actual treatment of cancers," Wolfe
said. But because ibuprofen is cheap, he feared it was "not sexy enough" for any
big drug company to sponsor.
Colon cancer is the second leading cause of cancer death in the United States
after lung cancer, and will kill 57,000 people this year, according to the
American Cancer Society.
